...Investor appetite for biotech is going strong in both the U.S. and Hong Kong, with Inhibrx...
...proposed to sell 4.7 million shares at $20-$23. Harmony markets Wakix pitolisant to treat excessive daytime sleepiness.Inhibrx Inc....
...valuation of $756.2 million. The biotech sold 7 million shares at $17, raising $119 million. Inhibrx...

...out Qiagen”).Inhibrx, Harmony near NASDAQ IPOsA pair of companies have set terms this week for their proposed IPOs.Inhibrx Inc....
...on T cell responses to COVID-19. BC Staff Nurtec ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony...

...23% stake in June (see “GSK-CureVac Deal Aims to Advance mRNA for Future Pandemics” ). Inhibrx Inc....
...$100 million. The biotech had initially filed for an IPO mid-2019, but withdrew in November. Inhibrx...
...Guanylate cyclase 2D membrane retina-specific BioCentury Staff Sanofi University of Florida Praxis Precision Medicines Inc. CureVac N.V. Harmony Biosciences Holdings Inc. Inhibrx Inc. Guanylate...

...testing for advanced solid tumors in China. Elpiscience gained China rights to ES101 (INBRX-105) from Inhibrx Inc....

...Biopharma Inc. 6/18/19 $4.6 Preclin Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Shanghai) 6/10/19 TBD Ph III Inhibrx Inc....

...Mirum Pharmaceuticals Inc. 6/21/19 $75.0 Ph III Scopus Biopharma Inc. 6/18/19 Up to $4.5 Preclin Inhibrx Inc....

...diseases, and is also developing several new molecular entities. Inhibrx files for $75M NASDAQ IPO Inhibrx Inc....
...to $74.8 million in a NASDAQ IPO underwritten by Evercore, Barclays, Nomura and Raymond James. Inhibrx...
...including orphan and more prevalent autoimmune diseases and orphan oncology indications. BC Staff LTI-01 LTI-03 Hansoh Pharmaceutical Group Co. Ltd. Inhibrx Inc. Lung...

...Innovent’s PD-1 mAb Tyvyt for Hodgkin Lymphoma" ). Inhibrx, Chiesi partner on rare disease candidate Inhibrx Inc....
...rights to develop and commercialize INBRX-101. Chiesi will make a $10 million equity investment in Inhibrx...
...million in upfront, profit sharing and milestone payments, plus royalties, if the option is exercised. Inhibrx...

...tyrosine kinase 3; KLA - Klotho α Jonathan Block, Associate Editor Xospata, gilteritinib (ASP2215) Astellas Pharma Inc. Chiesi Farmaceutici S.p.A. Inhibrx Inc. Iovance...

...them to deliver standout returns" (see "What Woodford Worries?" ). Viking backs Inhibrx with $40M Inhibrx Inc....
...existing investors RA Capital, Lilly Asia Ventures, ArrowMark Partners, WuXi Biologics Inc. (HKSE:2269) and Alexandria. Inhibrx...
...a MAS receptor agonist in Phase IIb testing to treat sarcopenia. Chris Lieu, Staff Writer Biophytis S.A. Insmed Inc. Inhibrx Inc. Woodford...